Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-12T11:30:45.999Z Has data issue: false hasContentIssue false

6 - Targeting acute myelogenous leukemia stem cells

from SECTION II - THERAPEUTIC IMPLICATIONS OF CANCER STEM CELLS

Published online by Cambridge University Press:  15 December 2009

By
Monica L. Guzman ,
Gerrit J. Schuurhuis  and
Craig T. Jordan
Edited by
William L. Farrar
Monica L. Guzman
Affiliation:
University of Rochester School of Medicine and Dentistry
Gerrit J. Schuurhuis
Affiliation:
VU University Medical Center
Craig T. Jordan
Affiliation:
University of Rochester Medical Center
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Cancer Stem Cells , pp. 93 - 108
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lapidot, T, Sirard, C, Vormoor, J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648.CrossRefGoogle ScholarPubMed
Bonnet, D, Dick, JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737.CrossRefGoogle ScholarPubMed
Blair, A, Hogge, , Ailles, , et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104–3112.Google ScholarPubMed
Sutherland, HJ, Blair, A, Zapf, RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood. 1996;87:4754–4761.Google ScholarPubMed
Fialkow, PJ, Jacobson, RJ, Papayannopoulou, T.Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125–130.CrossRefGoogle Scholar
Dube, ID, Gupta, CM, Kalousek, DK, et al. Cytogenetic studies of early myeloid progenitor compartments in Ph1-positive chronic myeloid leukaemia (CML). I. Persistence of Ph1-negative committed progenitors that are suppressed from differentiating in vivo. Br J Haematol. 1984;56:633–644.CrossRefGoogle ScholarPubMed
Schenk, TM, Keyhani, A, Bottcher, S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 1998;12:666–674.CrossRefGoogle ScholarPubMed
Jordan, CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 2002;16:559–562.CrossRefGoogle ScholarPubMed
Krivtsov, AV, Twomey, D, Feng, Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818–822.CrossRefGoogle ScholarPubMed
Yuan, Y, Zhou, L, Miyamoto, T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA. 2001;98:10398–10403.CrossRefGoogle ScholarPubMed
Moolgavkar, SH, Knudson, AG Jr. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst. 1981;66:1037–1052.CrossRefGoogle ScholarPubMed
Miyamoto, T, Weissman, IL, Akashi, K.AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA. 2000;97:7521–7526.CrossRefGoogle ScholarPubMed
Hong, D, Gupta, R, Ancliff, P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 2008;319:336–339.CrossRefGoogle ScholarPubMed
Huntly, BJ, Shigematsu, H, Deguchi, K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6:587–596.CrossRefGoogle Scholar
Neering, SJ, Bushnell, T, Sozer, S, et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007;110:2578–2585.CrossRefGoogle Scholar
Rhenen, A, Dongen, GA, Kelder, A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659–2666.CrossRefGoogle ScholarPubMed
Hosen, N, Park, CY, Tatsumi, N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104:11008–11013.CrossRefGoogle ScholarPubMed
Blair, A, Sutherland, HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol. 2000;28:660–671.CrossRefGoogle Scholar
Jordan, CT, Upchurch, D, Szilvassy, SJ, et al. The interleukin 3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–1784.CrossRefGoogle ScholarPubMed
Hope, KJ, Jin, L, Dick, JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738–743.CrossRefGoogle ScholarPubMed
Holyoake, TL, Jiang, X, Jorgensen, HG, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood. 2001;97:720–728.CrossRefGoogle ScholarPubMed
Guan, Y, Gerhard, B, Hogge, . Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101:3142–3149.CrossRefGoogle Scholar
Guzman, ML, Swiderski, CF, Howard, DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002;99:16220–16225.CrossRefGoogle ScholarPubMed
Ishikawa, F, Yoshida, S, Saito, Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315–1321.CrossRefGoogle ScholarPubMed
Costello, RT, Mallet, F, Gaugler, B, et al. Human acute myeloid leukemia CD34+/CD38− progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000;60:4403–4411.Google ScholarPubMed
Guzman, ML, Neering, SJ, Upchurch, D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307.CrossRefGoogle ScholarPubMed
Xu, Q, Simpson, SE, Scialla, TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003;102:972–980.CrossRefGoogle ScholarPubMed
Xu, Q, Thompson, JE, Carroll, M.mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005;106:4261–4268.CrossRefGoogle ScholarPubMed
Jamieson, CH, Ailles, , Dylla, SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–667.CrossRefGoogle ScholarPubMed
Guzman, ML, Rossi, RM, Neelakantan, S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007;110(13):4427–4435.CrossRefGoogle ScholarPubMed
Hamilton, A, Elrick, L, Myssina, S, et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia. 2006;20:1035–1039.CrossRefGoogle ScholarPubMed
Copland, M, Hamilton, A, Elrick, LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532–4539.CrossRefGoogle Scholar
Bhatia, R, Holtz, M, Niu, N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701–4707.CrossRefGoogle ScholarPubMed
Holtz, MS, Bhatia, R.Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk Lymphoma. 2004;45:237–245.CrossRefGoogle ScholarPubMed
Black, JH, McCubrey, JA, Willingham, MC, et al. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia. 2003;17:155–159.CrossRefGoogle ScholarPubMed
Urieto, JO, Liu, T, Black, JH, et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004;33:123–133.CrossRefGoogle ScholarPubMed
Yalcintepe, L, Frankel, AE, Hogge, . Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood. 2006;108:3530–3537.CrossRefGoogle ScholarPubMed
Hogge, , Yalcintepe, L, Wong, SH, et al. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res. 2006;12:1284–1291.CrossRefGoogle ScholarPubMed
Frankel, A, Liu, JS, Rizzieri, D, et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49:543–553.CrossRefGoogle ScholarPubMed
Taussig, DC, Pearce, DJ, Simpson, C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106:4086–4092.CrossRefGoogle ScholarPubMed
Hauswirth, AW, Florian, S, Printz, D, et al. Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells. Eur J Clin Invest. 2007;37:73–82.CrossRefGoogle ScholarPubMed
Vercauteren, S, Zapf, R, Sutherland, H.Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(−) AML patients express CD33. Cytotherapy. 2007;9:194–204.CrossRefGoogle ScholarPubMed
Stasi, R.Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther. 2008;8:527–540.CrossRefGoogle ScholarPubMed
Jin, L, Hope, KJ, Zhai, Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12:1167–1174.CrossRefGoogle ScholarPubMed
Krause, DS, Lazarides, K, Andrian, UH, et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12:1175–1180.CrossRefGoogle ScholarPubMed
Peled, A, Petit, I, Kollet, O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–848.CrossRefGoogle ScholarPubMed
Spoo, AC, Lubbert, M, Wierda, WG, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786–791.CrossRefGoogle ScholarPubMed
Tavor, S, Petit, I, Porozov, S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64:2817–2824.CrossRefGoogle Scholar
Gilliland, DG, Griffin, JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–1542.CrossRefGoogle ScholarPubMed
Meshinchi, S, Woods, WG, Stirewalt, DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89–94.CrossRefGoogle ScholarPubMed
Kottaridis, PD, Gale, RE, Frew, ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759.CrossRefGoogle ScholarPubMed
Kiyoi, H, Naoe, T, Nakano, Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–3080.Google ScholarPubMed
Kiyoi, H, Towatari, M, Yokota, S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333–1337.CrossRefGoogle ScholarPubMed
Levis, M, Murphy, KM, Pham, R, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood. 2005;106:673–680.CrossRefGoogle ScholarPubMed
Zhang, W, Konopleva, M, Shi, YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100:184–198.CrossRefGoogle ScholarPubMed
Corvera, S, Czech, MP. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol. 1998;8:442–446.CrossRefGoogle ScholarPubMed
Hennessy, BT, Smith, DL, Ram, PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004.CrossRefGoogle ScholarPubMed
Mayo, MW, Baldwin, AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55–62.Google ScholarPubMed
Baldwin, AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241–246.CrossRefGoogle ScholarPubMed
Bargou, RC, Emmerich, F, Krappmann, D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961–2969.CrossRefGoogle ScholarPubMed
Sweeney, C, Li, L, Shanmugam, R, et al. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res. 2004;10:5501–5507.CrossRefGoogle ScholarPubMed
Nakshatri, H, Bhat-Nakshatri, P, Martin, DA, et al. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 1997;17:3629–3639.CrossRefGoogle ScholarPubMed
Kim, JY, Lee, S, Hwangbo, B, et al. NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis. Biochem Biophys Res Commun. 2000;273:140–146.CrossRefGoogle ScholarPubMed
Guzman, ML, Rossi, RM, Karnischky, L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–4169.CrossRefGoogle ScholarPubMed
Letai, AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8:121–132.CrossRefGoogle ScholarPubMed
Cory, S, Adams, JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell. 2005;8:5–6.CrossRefGoogle ScholarPubMed
Konopleva, M, Contractor, R, Tsao, T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375–388.CrossRefGoogle ScholarPubMed
Martinez, A, Alonso, M, Castro, A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002;45:1292–1299.CrossRefGoogle ScholarPubMed
Guzman, ML, Li, X, Corbett, CA, et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007;110(13):4436–4444.CrossRefGoogle Scholar
Hassane, DC, Guzman, ML, Corbett, C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008;111(12):5654–5662.CrossRefGoogle Scholar
Klaus, A, Birchmeier, W.Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387–398.CrossRefGoogle ScholarPubMed
Hurlbut, GD, Kankel, MW, Lake, RJ, et al. Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol. 2007;19:166–175.CrossRefGoogle ScholarPubMed
Artavanis-Tsakonas, S, Rand, MD, Lake, RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776.CrossRefGoogle ScholarPubMed
Peacock, CD, Wang, Q, Gesell, GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA. 2007;104:4048–4053.CrossRefGoogle ScholarPubMed
Lauth, M, Toftgard, R.The Hedgehog pathway as a drug target in cancer therapy. Curr Opin Invest Drugs. 2007;8:457–461.Google ScholarPubMed
Gal, H, Amariglio, N, Trakhtenbrot, L, et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia. 2006;20:2147–2154.CrossRefGoogle ScholarPubMed
Rhenen, A, Moshaver, B, Kelder, A, et al. Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21:1700–1707.CrossRefGoogle ScholarPubMed
Milojkovic, D, Devereux, S, Westwood, NB, et al. Antiapoptotic microenvironment of acute myeloid leukemia. J Immunol. 2004;173:6745–6752.CrossRefGoogle ScholarPubMed
San Miguel, JF, Vidriales, MB, Lopez-Berges, C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746–1751.CrossRefGoogle ScholarPubMed
Venditti, A, Buccisano, F, Del Poeta, G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96:3948–3952.Google ScholarPubMed
Kern, W, Voskova, D, Schoch, C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104:3078–3085.CrossRefGoogle ScholarPubMed
Feller, N, Pol, MA, Stijn, A, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia. 2004;18:1380–1390.CrossRefGoogle ScholarPubMed
Rhenen, A, Feller, N, Kelder, A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520–6527.CrossRefGoogle ScholarPubMed
Goodell, MA, Rosenzweig, M, Kim, H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337–1345.CrossRefGoogle ScholarPubMed
Feuring-Buske, M, Hogge, . Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(−) progenitor cells from patients with acute myeloid leukemia. Blood. 2001;97:3882–3889.CrossRefGoogle ScholarPubMed
Wulf, GG, Wang, RY, Kuehnle, I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98:1166–1173.CrossRefGoogle ScholarPubMed
Cox, CV, Martin, HM, Kearns, PR, et al. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood. 2007;109:674–682.CrossRefGoogle ScholarPubMed
Quijano, CA, Moore, D, Arthur, D, et al. Cytogenetically aberrant cells are present in the CD34+CD33−CD38−CD19− marrow compartment in children with acute lymphoblastic leukemia. Leukemia. 1997;11:1508–1515.CrossRefGoogle ScholarPubMed
George, AA, Franklin, J, Kerkof, K, et al. Detection of leukemic cells in the CD34(+)CD38(−) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood. 2001;97:3925–3930.CrossRefGoogle ScholarPubMed
Cox, CV, Evely, RS, Oakhill, A, et al. Characterization of acute lymphoblastic leukemia progenitor cells. Blood. 2004;104:2919–2925.CrossRefGoogle ScholarPubMed
Cox, CV, Diamanti, P, Evely, RS, et al. Expression of CD133 in leukemia-initiating cells in childhood ALL. Blood. 2009;113:3287–3297.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×